


PHARMACEUTICAL 2017

BOMARIN

BIOMARIN PHARMACEUTICAL INC Rank 107 of 313





PHARMACEUTICAL 2017

BOMARIN

## BIOMARIN PHARMACEUTICAL INC Rank 107 of 313

The relative strengths and weaknesses of BIOMARIN PHARMACEUTICAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOMARIN PHARMACEUTICAL INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 123% points. The greatest weakness of BIOMARIN PHARMACEUTICAL INC is the variable Other Expenses, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is -70%, being 346% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	1,421,791
Cost of Goods Sold	209,620
Intangible Assets	750,819
Liabilities, Current	439,310
Liabilities, Non-Current	42,034
Other Assets	1,052,312
Other Compr. Net Income	-8,217
Other Expenses	982,989
Other Liabilities	776,071
Other Net Income	11,878
Property and Equipment	798,768
Research and Development	661,905
Revenues	1,116,854
Selling, General and Administrative Expense	476,593

Output Variable	Value in 1000 USD
Assets	4,023,690
Liabilities	1,257,415
Expenses	2,331,107
Stockholders Equity	2,766,275
Net Income	-1,202,375
Comprehensive Net Income	-1,206,484
Economic Capital Ratio	-70%

